Gatehouse Bio is a bio-data company. Gatehouse Bio has a collaboration with AstraZeneca for the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s AI-powered platform. The sRNAlytics platform identifies small RNA (sRNA) signatures in sequencing data and points to molecular pathways that correlate to or potentially drive disease. The company’s annotation library has more than 1.4 small RNA features that their machine learning algorithms use to recognize signals. Gatehouse joined AstraZeneca’s Boston Bio Hub Incubator in 2018.
The sRNA signatures discovered by GateHouse’s platform are biomarkers for disease, which can assist with classifying patients for clinical trials. As a proof-of-concept, GateHouse Bio used their sRNAlytics platform in collaboration with academic researchers to identify and validate biomarkers to identify pre-symptomatic and symptomatic Huntington’s disease.
Gatehouse Bio proposed using their technology platform in a study to study patient response sRNA signatures to COVID-19 disease which is caused by infection with the coronavirus SARS-CoV-2. The company will correlate their sRNA signatures that define biological processes affected by SARS and MERS to SARS-CoV-2. The study will analyze sRNA signatures correlated to inflammation, cytokine release, T-cell activation and fibrosis. Gatehouse expects to find host pathways impacted by SARS-CoV-2 infection and use this information to search their database of FDA approved drugs to accelerate the identification of potentially effective drugs. The sRNA signatures in patients with COVID-19 disease could be used as a prognostic test as well. Gatehouse Bio will analyze sRNA signatures correlated to inflammation, cytokine release, T-cell activation and fibrosis.
David W. Salzman
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: RNA-based and RNA-targeted therapeuticsA cluster of topics related to RNA-based therapeutics and RNA-targeted therapeutics. RNA-based therapeutics include RNA and oligonucleotide therapeutics that target RNA and proteins. RNA-targeted therapeutics include RNA and oligonucleotide therapeutics as well as small molecule drugs that target RNA.
- Cluster: Artificial intelligenceA cluster of topics related to artificial intelligence.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.